Author: "Lundgren, J." / Publication Year Range: This year - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Lundgren, J."' showing total 27 results

Start Over Author "Lundgren, J." Publication Year Range This year

27 results on '"Lundgren, J."'

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

Author: Tusch, E, Ryom, L, Pelchen-Matthews, A, Mocroft, A, Elbirt, D, Oprea, C, Günthard, H, Staehelin, C, Zangerle, R, Suarez, I, Vehreschild, J, Wit, F, Menozzi, M, d'Arminio Monforte, A, Spagnuolo, V, Pradier, C, Carlander, C, Suanzes, P, Wasmuth, J, Carr, A, Petoumenos, K, Borgans, F, Bonnet, F, De Wit, S, El-Sadr, W, Neesgaard, B, Jaschinski, N, Greenberg, L, Hosein, S, Gallant, J, Vannappagari, V, Young, L, Sabin, C, Lundgren, J, Peters, L, Reekie, J, Calvo, G, Dabis, F, Kirk, O, Law, M, Monforte, A, Morfeldt, L, Reiss, P, Weber, R, Lind-Thomsen, A, Brandt, R, Hillebreght, M, Zaheri, S, Scherrer, A, Schöni-Affolter, F, Rickenbach, M, Tavelli, A, Fanti, I, Leleux, O, Mourali, J, Marec, F, Boerg, E, Thulin, E, Sundström, A, Bartsch, G, Thompsen, G, Necsoi, C, Delforge, M, Fontas, E, Caissotti, C, Dollet, K, Mateu, S, Torres, F, Blance, A, Huang, R, Puhr, R, Laut, K, Kristensen, D, Phillips, A, Kamara, D, Smith, C, Hatleberg, C, Raben, D, Matthews, C, Bojesen, A, Grevsen, A, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Smit, C, Ross, M, Fux, C, Morlat, P, Friis-Møller, N, Kowalska, J, Bohlius, J, Bower, M, Fätkenheuer, G, Grulich, A, Sjøl, A, Meidahl, P, Iversen, J, Reiss, C, Hillebregt, M, Prins, J, Kuijpers, T, Scherpbier, H, van der Meer, J, Godfried, M, van der Poll, T, Nellen, F, Geerlings, S, van Vugt, M, Pajkrt, D, Bos, J, Wiersinga, W, van der Valk, M, Goorhuis, A, Hovius, J, van Eden, J, Henderiks, A, van Hes, A, Mutschelknauss, M, Nobel, H, Pijnappel, F, Jurriaans, S, Back, N, Zaaijer, H, Berkhout, B, Cornelissen, M, Schinkel, C, Thomas, X, Ziekenhuis, A, van den Berge, M, Stegeman, A, Baas, S, de Looff, L, Versteeg, D, Ziekenhuis, C, Pronk, M, Ammerlaan, H, De Munnik, E, Jansz, A, Tjhie, J, Wegdam, M, Deiman, B, Scharnhorst, V, van der Plas, A, Weijsenfeld, A, van der Ende, M, De Vries-Sluijs, T, van Gorp, E, Schurink, C, Nouwen, J, Verbon, A, Rijnders, B, Bax, H, van der Feltz, M, Bassant, N, van Beek, J, Vriesde, M, van Zonneveld, L, de Oude-Lubbers, A, van den Berg-Cameron, H, Bruinsma-Broekman, F, de Groot, J, de Man, M, Boucher, C, Koopmans, M, van Kampen, J, Pas, S, Mc–sophia, E, Driessen, G, van Rossum, A, van der Knaap, L, Visser, E, Branger, J, Rijkeboer-Mes, A, de Ven, C, Ziekenhuis, H, Schippers, E, van Nieuwkoop, C, van IJperen, J, Geilings, J, van der Hut, G, Franck, P, van Eeden, A, Brokking, W, Groot, M, Elsenburg, L, Damen, M, Kwa, I, Groeneveld, P, Bouwhuis, J, van den Berg, J, van Hulzen, A, van der Bliek, G, Bor, P, Bloembergen, P, Wolfhagen, M, Ruijs, G, Kroon, F, de Boer, M, Bauer, M, Jolink, H, Vollaard, A, Dorama, W, van Holten, N, Claas, E, Wessels, E, den Hollander, J, Pogany, K, Roukens, A, Kastelijns, M, Smit, J, Smit, E, Struik-Kalkman, D, Tearno, C, Bezemer, M, van Niekerk, T, Pontesilli, O, Lowe, S, Lashof, A, Posthouwer, D, Ackens, R, Schippers, J, Vergoossen, R, Weijenberg-Maes, B, van Loo, I, Havenith, T, Leyten, E, Gelinck, L, van Hartingsveld, A, Meerkerk, C, Wildenbeest, G, Mutsaers, J, Jansen, C, Mulder, J, Vrouenraets, S, Lauw, F, van Broekhuizen, M, Paap, H, Vlasblom, D, Smits, P, Zuiderzee, M, Weijer, S, El Moussaoui, R, Bosma, A, van Vonderen, M, van Houte, D, Kampschreur, L, Dijkstra, K, Faber, S, Weel, J, Kootstra, G, Delsing, C, van der Burg-van de Plas, M, Heins, H, Lucas, E, Kortmann, W, van Twillert, G, Stuart, J, Diederen, B, Pronk, D, van Truijen-Oud, F, van der Reijden, W, Jansen, R, Brinkman, K, van den Berk, G, Blok, W, Frissen, P, Lettinga, K, Schouten, W, Veenstra, J, Brouwer, C, Geerders, G, Hoeksema, K, Kleene, M, van der Meché, I, Spelbrink, M, Sulman, H, Toonen, A, Wijnands, S, Kwa, D, Witte, E, Koopmans, P, Keuter, M, van der Ven, A, ter Hofstede, H, Dofferhoff, A, van Crevel, R, Albers, M, Bosch, M, Grintjes-Huisman, K, Zomer, B, Stelma, F, Rahamat-Langendoen, J, Burger, D, Richter, C, Gisolf, E, Hassing, R, ter Beest, G, van Bentum, P, Langebeek, N, Tiemessen, R, Swanink, C, van Lelyveld, S, Soetekouw, R, Hulshoff, N, van der Prijt, L, van der Swaluw, J, Bermon, N, Herpers, B, Veenendaal, D, Verhagen, D, van Wijk, M, Ziekenhuis, S, van Kasteren, M, Brouwer, A, de Wiel, B, Kuipers, M, Santegoets, R, van der Ven, B, Marcelis, J, Buiting, A, Kabel, P, Bierman, W, Scholvinck, H, Wilting, K, Stienstra, Y, Jonge, H, van der Meulen, P, de Weerd, D, Ludwig-Roukema, J, Niesters, H, Riezebos-Brilman, A, van Leer-Buter, C, Knoester, M, Hoepelman, A, Mudrikova, T, Ellerbroek, P, Oosterheert, J, Arends, J, Barth, R, Wassenberg, M, Schadd, E, van Elst-Laurijssen, D, van Oers-Hazelzet, E, Vervoort, S, van Berkel, M, Schuurman, R, Verduyn-Lunel, F, Wensing, A, Peters, E, van Agtmael, M, Bomers, M, de Vocht, J, Heitmuller, M, Laan, L, Pettersson, A, Vandenbroucke-Grauls, C, Ang, C, Kinderziekenhuis, W, Geelen, S, Wolfs, T, Bont, L, Nauta, N, Bezemer, D, van Sighem, A, Boender, T, de Jong, A, Bergsma, D, Hoekstra, P, de Lang, A, Grivell, S, Jansen, A, Rademaker, M, Raethke, M, Meijering, R, Schnörr, S, de Groot, L, van den Akker, M, Bakker, Y, Claessen, E, El Berkaoui, A, Koops, J, Kruijne, E, Lodewijk, C, Munjishvili, L, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Rutkens, T, van de Sande, L, Schoorl, M, Timmerman, A, Tuijn, E, Veenenberg, L, van der Vliet, S, Wisse, A, Woudstra, T, Tuk, B, Dupon, M, Gaborieau, V, Lacoste, D, Malvy, D, Mercié, P, Neau, D, Pellegrin, J, Tchamgoué, S, Lazaro, E, Cazanave, C, Vandenhende, M, Vareil, M, Gérard, Y, Blanco, P, Bouchet, S, Breilh, D, Fleury, H, Pellegrin, I, Chêne, G, Thiébaut, R, Wittkop, L, Lawson-Ayayi, S, Gimbert, A, Desjardin, S, Lacaze-Buzy, L, Petrov-Sanchez, V, André, K, Bernard, N, Caubet, O, Caunegre, L, Chossat, I, Courtault, C, Dauchy, F, De Witte, S, Dondia, D, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Ferrand, H, Gerard, Y, Greib, C, Hessamfar, M, Imbert, Y, Lataste, P, Marie, J, Mechain, M, Monlun, E, Ochoa, A, Pistone, T, Raymond, I, Receveur, M, Rispal, P, Sorin, L, Valette, C, Viallard, J, Wille, H, Wirth, G, Lafon, M, Trimoulet, P, Bellecave, P, Tumiotto, C, Haramburu, F, Miremeont-Salamé, G, Blaizeau, M, Decoin, M, Hannapier, C, Lenaud, E, Pougetoux, A, Delveaux, S, D’Ivernois, C, Diarra, F, Uwamaliya-Nziyumvira, B, Palmer, G, Conte, V, Sapparrart, V, Law, C, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Lau, H, Bloch, M, Baker, D, Cooper, D, O’Sullivan, M, Nolan, D, Guelfi, G, Calvo, C, Domingo, P, Sambeat, M, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gennotte, A, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, M, Semaille, P, Van Laethem, Y, Neaton, C, Krum, E, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, D, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, L, Sampson, J, Baxter, J, Gazzard, B, Horban, A, Karpov, I, Losso, M, Pedersen, C, Ristola, M, Rockstroh, J, Fischer, A, Larsen, J, Podlekareva, D, Cozzi-Lepri, A, Shepherd, L, Schultze, A, Amele, S, Kundro, M, Schmied, B, Wien, P, Vassilenko, A, Mitsura, V, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Begovac, J, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Møller, N, Ostergaard, L, Wiese, L, Nielsen, L, Zilmer, K, Smidt, J, Siseklinik, N, Aho, I, Viard, J, Duvivier, C, Schmidt, R, Degen, O, Stellbrink, H, Stefan, C, Goethe, J, Bogner, J, Chkhartishvili, N, Gargalianos, P, Xylomenos, G, Armenis, K, Sambatakou, H, Szlávik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Sthoeger, Z, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Annunziata, O, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Matulionyte, R, Staub, T, Hemmer, R, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak-Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer-Lisewska, I, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Panteleev, A, Panteleev, O, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Blokhina, I, Novogrod, N, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Miró, J, Moreno, S, Rodriguez, J, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gutierrez, M, Mateo, G, Laporte, J, Sonnerborg, A, Brännström, I, Flamholc, L, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Johnson, A, Simons, E, Johnson, M, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Morfeldt, C, Thulin, G, Åkerlund, B, Koppel, K, Karlsson, A, Håkangård, C, Castelli, F, Cauda, R, Perri, G, Iardino, R, Ippolito, G, Marchetti, G, Perno, C, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Calza, L, Capobianchi, M, Cingolani, A, Cinque, P, De Luca, A, Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marcotullio, S, Monno, L, Nozza, S, Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, P, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Milini, P, Rizzardini, G, Moioli, M, Piolini, R, Salpietro, S, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Orlando, R, Bonadies, G, Martino, F, Gentile, I, Maddaloni, L, Cattelan, A, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, M, Cristaudo, A, Baldin, G, Capozzi, M, Cicalini, S, Sulekova, L, Iaiani, G, Latini, A, Mastrorosa, I, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, Del Vecchio, R, Francisci, D, Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Central, C, Dellamonica, P, Bernard, E, Courjon, J, Cua, E, De Salvador-Guillouet, F, Durant, J, Etienne, C, Ferrando, S, Mondain-Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost-Keller, B, Pugliese, P, Rio, V, Risso, K, Roger, P, Aubert, V, Bernasconi, E, Böni, J, Braun, D, Bucher, H, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Haerry, D, Hasse, B, Hirsch, H, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B, Marzolini, C, Metzner, K, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Yerly, S, Valk, M, Hutchinson, J, Rupasinghe, D, Han, W, Appoyer, H, Vera, J, Broster, B, Barbour, L, Carney, D, Greenland, L, Coughlan, R, Saint-Pierre, C, Stephan, C, Bucht, M, Chokoshvili, O, Borghi, V, Casabona, J, Miro, J, Lampe, F, Burns, F, Chaloner, C, Muccini, C, Lolatto, R, Sönnerborg, A, Nowak, P, Vesterbacka, J, Mattsson, L, Carrick, D, Stigsäter, K, Kusejko, K, Schulze, N, Franke, B, Rooney, J, Mcnicholl, I, Garges, H, Campo, R, Volny-Anne, A, Dedes, N, Williams, E, Bruguera, A, Volny-Anne, R, Mendão, L, Timiryasova, A, Fursa, O, Jakobsen, M, Kraef, C, Gardizi, M, Andersen, K, Kumar, L, Elsing, T, Shahi, S, Valdenmaiier, O, Bansi-Matharu, L, Byonanebye, D, Bannister, W, Roen, A, Null, N, Tusch, Erich, Ryom, Lene, Pelchen-Matthews, Annegret, Mocroft, Amanda, Elbirt, Daniel, Oprea, Cristiana, Günthard, Huldrych F, Staehelin, Cornelia, Zangerle, Robert, Suarez, Isabelle, Vehreschild, Jörg Janne, Wit, Ferdinand, Menozzi, Marianna, d'Arminio Monforte, Antonella, Spagnuolo, Vincenzo, Pradier, Christian, Carlander, Christina, Suanzes, Paula, Wasmuth, Jan-Christian, Carr, Andrew, Petoumenos, Kathy, Borgans, Frauke, Bonnet, Fabrice, De Wit, Stephane, El-Sadr, Wafaa, Neesgaard, Bastian, Jaschinski, Nadine, Greenberg, Lauren, Hosein, Sean R, Gallant, Joel, Vannappagari, Vani, Young, Lital, Sabin, Caroline, Lundgren, Jens, Peters, Lars, Reekie, Joanne, Monforte, A d’Arminio, Brandt, R Salbøl, Wit, F W N M, Marec, F Le, Laut, K Grønborg, Sabin, C A, Phillips, A N, Kamara, D A, Smith, C J, Hatleberg, C I, Brandt, R S, Grevsen, A L, Lundgren, J D, Fux, C A, Monforte, A d'Arminio, Iversen, J S, Reiss, Central P, Prins, J M, Kuijpers, T W, Scherpbier, H J, van der Meer, J T M, Godfried, M H, Nellen, F J B, Geerlings, S E, Bos, J C, Wiersinga, W J, Hovius, J W, van Hes, A M H, Nobel, H E, Pijnappel, F J J, Back, N K T, Zaaijer, H L, Cornelissen, M T E, Schinkel, C J, Thomas, X V, Ziekenhuis, Admiraal De Ruyter, de Looff, L Hage, Ziekenhuis, Catharina, Pronk, M J H, Ammerlaan, H S M, De Munnik, E S, Jansz, A R, Wegdam, M C A, Weijsenfeld, A M, van der Ende, M E, De Vries-Sluijs, T E M S, van Gorp, E C M, Schurink, C A M, Nouwen, J L, Rijnders, B J A, Bax, H I, van Beek, J E A, van Zonneveld, L M, van den Berg-Cameron, H J, Bruinsma-Broekman, F B, de Man, M de Zeeuw, Boucher, C A B, Koopmans, M P G, van Kampen, J J A, Pas, S D, MC–Sophia, Erasmus, Driessen, G J A, van Rossum, A M C, van der Knaap, L C, de Ven, C J H M Duijf-van, Ziekenhuis, Haga, Schippers, E F, van IJperen, J M, Franck, P F H, Elsenburg, L J M, Kwa, I S, Groeneveld, P H P, Bouwhuis, J W, van den Berg, J F, van Hulzen, A G W, van der Bliek, G L, Bor, P C J, Wolfhagen, M J H M, Ruijs, G J H M, Kroon, F P, de Boer, M G J, Bauer, M P, Vollaard, A M, Claas, E C J, den Hollander, J G, Smit, J V, Lowe, S H, Lashof, A M L Oude, Ackens, R P, van Loo, I H M, Havenith, T R A, Leyten, E M S, Gelinck, L B S, Wildenbeest, G S, Mutsaers, J A E M, Jansen, C L, Mulder, J W, Vrouenraets, S M E, Lauw, F N, van Broekhuizen, M C, Vlasblom, D J, Smits, P H M, Zuiderzee, M C, Bosma, A S, van Vonderen, M G A, van Houte, D P F, Kampschreur, L M, Kootstra, G J, Delsing, C E, Stuart, J W T Cohen, Diederen, B M W, van Truijen-Oud, F A, van der Reijden, W A, van den Berk, G E L, Blok, W L, Frissen, P H J, Lettinga, K D, Schouten, W E M, Brouwer, C J, Geerders, G F, Kleene, M J, van der Meché, I B, Toonen, A J M, Koopmans, P P, van der Ven, A J A M, ter Hofstede, H J M, Dofferhoff, A S M, Bosch, M E W, Grintjes-Huisman, K J T, Zomer, B J, Stelma, F F, Gisolf, E H, Hassing, R J, van Bentum, P H M, Swanink, C M A, van Lelyveld, S F L, van der Prijt, L M M, Herpers, B L, Verhagen, D W M, Ziekenhuis, St Elisabeth, van Kasteren, M E E, Brouwer, A E, de Wiel, B A F M de Kruijf-van, Santegoets, R M W J, Marcelis, J H, Buiting, A G M, Kabel, P J, Bierman, W F W, Wilting, K R, Jonge, H de Groot-de, van der Meulen, P A, de Weerd, D A, Niesters, H G M, van Leer-Buter, C C, Hoepelman, A I M, Ellerbroek, P M, Oosterheert, J J, Arends, J E, Barth, R E, Wassenberg, M W M, Schadd, E M, van Elst-Laurijssen, D H M, van Oers-Hazelzet, E E B, Wensing, A M J, Peters, E J G, van Agtmael, M A, Laan, L M, Pettersson, A M, Vandenbroucke-Grauls, C M J E, Ang, C W, Kinderziekenhuis, Wilhelmina, Geelen, S P M, Wolfs, T F W, Bont, L J, Bezemer, D O, van Sighem, A I, Boender, T S, Rademaker, M J, Pellegrin, J L, Vareil, M O, Dauchy, F A, Receveur, M C, Vandenhende, M A, Viallard, J F, Lafon, Me, Blaizeau, M J, Boerg, Eloïse, Law, Central M, Calvo, Central G, Sambeat, M A, Gennotte, A F, Payen, M C, Neaton, Central J, El-Sadr, W M, Abrams, D I, Crane, L R, Fischer, A H, Larsen, J F, Wien, Pulmologisches Zentrum der Stadt, Mitsura, V M, Møller, N F, Nielsen, L N, Smidt, Jelena, Siseklinik, Nakkusosakond, Viard, J-P, Stellbrink, H J, Goethe, J W, Sthoeger, Z M, Monforte, A D’Arminio, Annunziata, Ospedale S Maria, Blokhina, I N, Novogrod, Nizhny, Gatell, J M, Miró, J M, Rodriguez, J M, Laporte, J M, Johnson, A M, Johnson, M A, Morfeldt, Central L, Perri, G Di, Marchetti, G C, Perno, C F, Caputo, S Lo, Capobianchi, M R, Biagio, A Di, Roldan, E Quiros, Santoro, M M, Caro, A Di, Manconi, P E, Moioli, M C, Ridolfo, A L, Martino, F Di, Cattelan, A M, Ursitti, M A, Sulekova, L Fontanelli, Plazzi, M M, Del Vecchio, R Fontana, Giuli, C Di, Orofino, G C, Roger, P M, Braun, D L, Bucher, H C, Günthard, H F, Hirsch, H H, Kouyos, R D, de Tejada, B Martinez, Metzner, K J, Scherrer, A U, Valk, Marc vd, Han, W Min, Saint-Pierre, C H U, Miro, J M, Wasmuth, J C, Vehreschild, J J, McNicholl, I, Williams, E D, Volny-Anne, R Campo Alain, Dedes, Nikos, Mendão, Luis, Jakobsen, M L, Kumar, L Ramesh, Elsing, T W, null, null, Tusch, E, Ryom, L, Pelchen-Matthews, A, Mocroft, A, Elbirt, D, Oprea, C, Günthard, H, Staehelin, C, Zangerle, R, Suarez, I, Vehreschild, J, Wit, F, Menozzi, M, d'Arminio Monforte, A, Spagnuolo, V, Pradier, C, Carlander, C, Suanzes, P, Wasmuth, J, Carr, A, Petoumenos, K, Borgans, F, Bonnet, F, De Wit, S, El-Sadr, W, Neesgaard, B, Jaschinski, N, Greenberg, L, Hosein, S, Gallant, J, Vannappagari, V, Young, L, Sabin, C, Lundgren, J, Peters, L, Reekie, J, Calvo, G, Dabis, F, Kirk, O, Law, M, Monforte, A, Morfeldt, L, Reiss, P, Weber, R, Lind-Thomsen, A, Brandt, R, Hillebreght, M, Zaheri, S, Scherrer, A, Schöni-Affolter, F, Rickenbach, M, Tavelli, A, Fanti, I, Leleux, O, Mourali, J, Marec, F, Boerg, E, Thulin, E, Sundström, A, Bartsch, G, Thompsen, G, Necsoi, C, Delforge, M, Fontas, E, Caissotti, C, Dollet, K, Mateu, S, Torres, F, Blance, A, Huang, R, Puhr, R, Laut, K, Kristensen, D, Phillips, A, Kamara, D, Smith, C, Hatleberg, C, Raben, D, Matthews, C, Bojesen, A, Grevsen, A, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Smit, C, Ross, M, Fux, C, Morlat, P, Friis-Møller, N, Kowalska, J, Bohlius, J, Bower, M, Fätkenheuer, G, Grulich, A, Sjøl, A, Meidahl, P, Iversen, J, Reiss, C, Hillebregt, M, Prins, J, Kuijpers, T, Scherpbier, H, van der Meer, J, Godfried, M, van der Poll, T, Nellen, F, Geerlings, S, van Vugt, M, Pajkrt, D, Bos, J, Wiersinga, W, van der Valk, M, Goorhuis, A, Hovius, J, van Eden, J, Henderiks, A, van Hes, A, Mutschelknauss, M, Nobel, H, Pijnappel, F, Jurriaans, S, Back, N, Zaaijer, H, Berkhout, B, Cornelissen, M, Schinkel, C, Thomas, X, Ziekenhuis, A, van den Berge, M, Stegeman, A, Baas, S, de Looff, L, Versteeg, D, Ziekenhuis, C, Pronk, M, Ammerlaan, H, De Munnik, E, Jansz, A, Tjhie, J, Wegdam, M, Deiman, B, Scharnhorst, V, van der Plas, A, Weijsenfeld, A, van der Ende, M, De Vries-Sluijs, T, van Gorp, E, Schurink, C, Nouwen, J, Verbon, A, Rijnders, B, Bax, H, van der Feltz, M, Bassant, N, van Beek, J, Vriesde, M, van Zonneveld, L, de Oude-Lubbers, A, van den Berg-Cameron, H, Bruinsma-Broekman, F, de Groot, J, de Man, M, Boucher, C, Koopmans, M, van Kampen, J, Pas, S, Mc–sophia, E, Driessen, G, van Rossum, A, van der Knaap, L, Visser, E, Branger, J, Rijkeboer-Mes, A, de Ven, C, Ziekenhuis, H, Schippers, E, van Nieuwkoop, C, van IJperen, J, Geilings, J, van der Hut, G, Franck, P, van Eeden, A, Brokking, W, Groot, M, Elsenburg, L, Damen, M, Kwa, I, Groeneveld, P, Bouwhuis, J, van den Berg, J, van Hulzen, A, van der Bliek, G, Bor, P, Bloembergen, P, Wolfhagen, M, Ruijs, G, Kroon, F, de Boer, M, Bauer, M, Jolink, H, Vollaard, A, Dorama, W, van Holten, N, Claas, E, Wessels, E, den Hollander, J, Pogany, K, Roukens, A, Kastelijns, M, Smit, J, Smit, E, Struik-Kalkman, D, Tearno, C, Bezemer, M, van Niekerk, T, Pontesilli, O, Lowe, S, Lashof, A, Posthouwer, D, Ackens, R, Schippers, J, Vergoossen, R, Weijenberg-Maes, B, van Loo, I, Havenith, T, Leyten, E, Gelinck, L, van Hartingsveld, A, Meerkerk, C, Wildenbeest, G, Mutsaers, J, Jansen, C, Mulder, J, Vrouenraets, S, Lauw, F, van Broekhuizen, M, Paap, H, Vlasblom, D, Smits, P, Zuiderzee, M, Weijer, S, El Moussaoui, R, Bosma, A, van Vonderen, M, van Houte, D, Kampschreur, L, Dijkstra, K, Faber, S, Weel, J, Kootstra, G, Delsing, C, van der Burg-van de Plas, M, Heins, H, Lucas, E, Kortmann, W, van Twillert, G, Stuart, J, Diederen, B, Pronk, D, van Truijen-Oud, F, van der Reijden, W, Jansen, R, Brinkman, K, van den Berk, G, Blok, W, Frissen, P, Lettinga, K, Schouten, W, Veenstra, J, Brouwer, C, Geerders, G, Hoeksema, K, Kleene, M, van der Meché, I, Spelbrink, M, Sulman, H, Toonen, A, Wijnands, S, Kwa, D, Witte, E, Koopmans, P, Keuter, M, van der Ven, A, ter Hofstede, H, Dofferhoff, A, van Crevel, R, Albers, M, Bosch, M, Grintjes-Huisman, K, Zomer, B, Stelma, F, Rahamat-Langendoen, J, Burger, D, Richter, C, Gisolf, E, Hassing, R, ter Beest, G, van Bentum, P, Langebeek, N, Tiemessen, R, Swanink, C, van Lelyveld, S, Soetekouw, R, Hulshoff, N, van der Prijt, L, van der Swaluw, J, Bermon, N, Herpers, B, Veenendaal, D, Verhagen, D, van Wijk, M, Ziekenhuis, S, van Kasteren, M, Brouwer, A, de Wiel, B, Kuipers, M, Santegoets, R, van der Ven, B, Marcelis, J, Buiting, A, Kabel, P, Bierman, W, Scholvinck, H, Wilting, K, Stienstra, Y, Jonge, H, van der Meulen, P, de Weerd, D, Ludwig-Roukema, J, Niesters, H, Riezebos-Brilman, A, van Leer-Buter, C, Knoester, M, Hoepelman, A, Mudrikova, T, Ellerbroek, P, Oosterheert, J, Arends, J, Barth, R, Wassenberg, M, Schadd, E, van Elst-Laurijssen, D, van Oers-Hazelzet, E, Vervoort, S, van Berkel, M, Schuurman, R, Verduyn-Lunel, F, Wensing, A, Peters, E, van Agtmael, M, Bomers, M, de Vocht, J, Heitmuller, M, Laan, L, Pettersson, A, Vandenbroucke-Grauls, C, Ang, C, Kinderziekenhuis, W, Geelen, S, Wolfs, T, Bont, L, Nauta, N, Bezemer, D, van Sighem, A, Boender, T, de Jong, A, Bergsma, D, Hoekstra, P, de Lang, A, Grivell, S, Jansen, A, Rademaker, M, Raethke, M, Meijering, R, Schnörr, S, de Groot, L, van den Akker, M, Bakker, Y, Claessen, E, El Berkaoui, A, Koops, J, Kruijne, E, Lodewijk, C, Munjishvili, L, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Rutkens, T, van de Sande, L, Schoorl, M, Timmerman, A, Tuijn, E, Veenenberg, L, van der Vliet, S, Wisse, A, Woudstra, T, Tuk, B, Dupon, M, Gaborieau, V, Lacoste, D, Malvy, D, Mercié, P, Neau, D, Pellegrin, J, Tchamgoué, S, Lazaro, E, Cazanave, C, Vandenhende, M, Vareil, M, Gérard, Y, Blanco, P, Bouchet, S, Breilh, D, Fleury, H, Pellegrin, I, Chêne, G, Thiébaut, R, Wittkop, L, Lawson-Ayayi, S, Gimbert, A, Desjardin, S, Lacaze-Buzy, L, Petrov-Sanchez, V, André, K, Bernard, N, Caubet, O, Caunegre, L, Chossat, I, Courtault, C, Dauchy, F, De Witte, S, Dondia, D, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Ferrand, H, Gerard, Y, Greib, C, Hessamfar, M, Imbert, Y, Lataste, P, Marie, J, Mechain, M, Monlun, E, Ochoa, A, Pistone, T, Raymond, I, Receveur, M, Rispal, P, Sorin, L, Valette, C, Viallard, J, Wille, H, Wirth, G, Lafon, M, Trimoulet, P, Bellecave, P, Tumiotto, C, Haramburu, F, Miremeont-Salamé, G, Blaizeau, M, Decoin, M, Hannapier, C, Lenaud, E, Pougetoux, A, Delveaux, S, D’Ivernois, C, Diarra, F, Uwamaliya-Nziyumvira, B, Palmer, G, Conte, V, Sapparrart, V, Law, C, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Lau, H, Bloch, M, Baker, D, Cooper, D, O’Sullivan, M, Nolan, D, Guelfi, G, Calvo, C, Domingo, P, Sambeat, M, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gennotte, A, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, M, Semaille, P, Van Laethem, Y, Neaton, C, Krum, E, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, D, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, L, Sampson, J, Baxter, J, Gazzard, B, Horban, A, Karpov, I, Losso, M, Pedersen, C, Ristola, M, Rockstroh, J, Fischer, A, Larsen, J, Podlekareva, D, Cozzi-Lepri, A, Shepherd, L, Schultze, A, Amele, S, Kundro, M, Schmied, B, Wien, P, Vassilenko, A, Mitsura, V, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Begovac, J, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Møller, N, Ostergaard, L, Wiese, L, Nielsen, L, Zilmer, K, Smidt, J, Siseklinik, N, Aho, I, Viard, J, Duvivier, C, Schmidt, R, Degen, O, Stellbrink, H, Stefan, C, Goethe, J, Bogner, J, Chkhartishvili, N, Gargalianos, P, Xylomenos, G, Armenis, K, Sambatakou, H, Szlávik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Sthoeger, Z, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Annunziata, O, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Matulionyte, R, Staub, T, Hemmer, R, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak-Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer-Lisewska, I, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Panteleev, A, Panteleev, O, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Blokhina, I, Novogrod, N, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Miró, J, Moreno, S, Rodriguez, J, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gutierrez, M, Mateo, G, Laporte, J, Sonnerborg, A, Brännström, I, Flamholc, L, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Johnson, A, Simons, E, Johnson, M, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Morfeldt, C, Thulin, G, Åkerlund, B, Koppel, K, Karlsson, A, Håkangård, C, Castelli, F, Cauda, R, Perri, G, Iardino, R, Ippolito, G, Marchetti, G, Perno, C, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Calza, L, Capobianchi, M, Cingolani, A, Cinque, P, De Luca, A, Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marcotullio, S, Monno, L, Nozza, S, Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, P, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Milini, P, Rizzardini, G, Moioli, M, Piolini, R, Salpietro, S, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Orlando, R, Bonadies, G, Martino, F, Gentile, I, Maddaloni, L, Cattelan, A, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, M, Cristaudo, A, Baldin, G, Capozzi, M, Cicalini, S, Sulekova, L, Iaiani, G, Latini, A, Mastrorosa, I, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, Del Vecchio, R, Francisci, D, Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Central, C, Dellamonica, P, Bernard, E, Courjon, J, Cua, E, De Salvador-Guillouet, F, Durant, J, Etienne, C, Ferrando, S, Mondain-Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost-Keller, B, Pugliese, P, Rio, V, Risso, K, Roger, P, Aubert, V, Bernasconi, E, Böni, J, Braun, D, Bucher, H, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Haerry, D, Hasse, B, Hirsch, H, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B, Marzolini, C, Metzner, K, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Yerly, S, Valk, M, Hutchinson, J, Rupasinghe, D, Han, W, Appoyer, H, Vera, J, Broster, B, Barbour, L, Carney, D, Greenland, L, Coughlan, R, Saint-Pierre, C, Stephan, C, Bucht, M, Chokoshvili, O, Borghi, V, Casabona, J, Miro, J, Lampe, F, Burns, F, Chaloner, C, Muccini, C, Lolatto, R, Sönnerborg, A, Nowak, P, Vesterbacka, J, Mattsson, L, Carrick, D, Stigsäter, K, Kusejko, K, Schulze, N, Franke, B, Rooney, J, Mcnicholl, I, Garges, H, Campo, R, Volny-Anne, A, Dedes, N, Williams, E, Bruguera, A, Volny-Anne, R, Mendão, L, Timiryasova, A, Fursa, O, Jakobsen, M, Kraef, C, Gardizi, M, Andersen, K, Kumar, L, Elsing, T, Shahi, S, Valdenmaiier, O, Bansi-Matharu, L, Byonanebye, D, Bannister, W, Roen, A, Null, N, Tusch, Erich, Ryom, Lene, Pelchen-Matthews, Annegret, Mocroft, Amanda, Elbirt, Daniel, Oprea, Cristiana, Günthard, Huldrych F, Staehelin, Cornelia, Zangerle, Robert, Suarez, Isabelle, Vehreschild, Jörg Janne, Wit, Ferdinand, Menozzi, Marianna, d'Arminio Monforte, Antonella, Spagnuolo, Vincenzo, Pradier, Christian, Carlander, Christina, Suanzes, Paula, Wasmuth, Jan-Christian, Carr, Andrew, Petoumenos, Kathy, Borgans, Frauke, Bonnet, Fabrice, De Wit, Stephane, El-Sadr, Wafaa, Neesgaard, Bastian, Jaschinski, Nadine, Greenberg, Lauren, Hosein, Sean R, Gallant, Joel, Vannappagari, Vani, Young, Lital, Sabin, Caroline, Lundgren, Jens, Peters, Lars, Reekie, Joanne, Monforte, A d’Arminio, Brandt, R Salbøl, Wit, F W N M, Marec, F Le, Laut, K Grønborg, Sabin, C A, Phillips, A N, Kamara, D A, Smith, C J, Hatleberg, C I, Brandt, R S, Grevsen, A L, Lundgren, J D, Fux, C A, Monforte, A d'Arminio, Iversen, J S, Reiss, Central P, Prins, J M, Kuijpers, T W, Scherpbier, H J, van der Meer, J T M, Godfried, M H, Nellen, F J B, Geerlings, S E, Bos, J C, Wiersinga, W J, Hovius, J W, van Hes, A M H, Nobel, H E, Pijnappel, F J J, Back, N K T, Zaaijer, H L, Cornelissen, M T E, Schinkel, C J, Thomas, X V, Ziekenhuis, Admiraal De Ruyter, de Looff, L Hage, Ziekenhuis, Catharina, Pronk, M J H, Ammerlaan, H S M, De Munnik, E S, Jansz, A R, Wegdam, M C A, Weijsenfeld, A M, van der Ende, M E, De Vries-Sluijs, T E M S, van Gorp, E C M, Schurink, C A M, Nouwen, J L, Rijnders, B J A, Bax, H I, van Beek, J E A, van Zonneveld, L M, van den Berg-Cameron, H J, Bruinsma-Broekman, F B, de Man, M de Zeeuw, Boucher, C A B, Koopmans, M P G, van Kampen, J J A, Pas, S D, MC–Sophia, Erasmus, Driessen, G J A, van Rossum, A M C, van der Knaap, L C, de Ven, C J H M Duijf-van, Ziekenhuis, Haga, Schippers, E F, van IJperen, J M, Franck, P F H, Elsenburg, L J M, Kwa, I S, Groeneveld, P H P, Bouwhuis, J W, van den Berg, J F, van Hulzen, A G W, van der Bliek, G L, Bor, P C J, Wolfhagen, M J H M, Ruijs, G J H M, Kroon, F P, de Boer, M G J, Bauer, M P, Vollaard, A M, Claas, E C J, den Hollander, J G, Smit, J V, Lowe, S H, Lashof, A M L Oude, Ackens, R P, van Loo, I H M, Havenith, T R A, Leyten, E M S, Gelinck, L B S, Wildenbeest, G S, Mutsaers, J A E M, Jansen, C L, Mulder, J W, Vrouenraets, S M E, Lauw, F N, van Broekhuizen, M C, Vlasblom, D J, Smits, P H M, Zuiderzee, M C, Bosma, A S, van Vonderen, M G A, van Houte, D P F, Kampschreur, L M, Kootstra, G J, Delsing, C E, Stuart, J W T Cohen, Diederen, B M W, van Truijen-Oud, F A, van der Reijden, W A, van den Berk, G E L, Blok, W L, Frissen, P H J, Lettinga, K D, Schouten, W E M, Brouwer, C J, Geerders, G F, Kleene, M J, van der Meché, I B, Toonen, A J M, Koopmans, P P, van der Ven, A J A M, ter Hofstede, H J M, Dofferhoff, A S M, Bosch, M E W, Grintjes-Huisman, K J T, Zomer, B J, Stelma, F F, Gisolf, E H, Hassing, R J, van Bentum, P H M, Swanink, C M A, van Lelyveld, S F L, van der Prijt, L M M, Herpers, B L, Verhagen, D W M, Ziekenhuis, St Elisabeth, van Kasteren, M E E, Brouwer, A E, de Wiel, B A F M de Kruijf-van, Santegoets, R M W J, Marcelis, J H, Buiting, A G M, Kabel, P J, Bierman, W F W, Wilting, K R, Jonge, H de Groot-de, van der Meulen, P A, de Weerd, D A, Niesters, H G M, van Leer-Buter, C C, Hoepelman, A I M, Ellerbroek, P M, Oosterheert, J J, Arends, J E, Barth, R E, Wassenberg, M W M, Schadd, E M, van Elst-Laurijssen, D H M, van Oers-Hazelzet, E E B, Wensing, A M J, Peters, E J G, van Agtmael, M A, Laan, L M, Pettersson, A M, Vandenbroucke-Grauls, C M J E, Ang, C W, Kinderziekenhuis, Wilhelmina, Geelen, S P M, Wolfs, T F W, Bont, L J, Bezemer, D O, van Sighem, A I, Boender, T S, Rademaker, M J, Pellegrin, J L, Vareil, M O, Dauchy, F A, Receveur, M C, Vandenhende, M A, Viallard, J F, Lafon, Me, Blaizeau, M J, Boerg, Eloïse, Law, Central M, Calvo, Central G, Sambeat, M A, Gennotte, A F, Payen, M C, Neaton, Central J, El-Sadr, W M, Abrams, D I, Crane, L R, Fischer, A H, Larsen, J F, Wien, Pulmologisches Zentrum der Stadt, Mitsura, V M, Møller, N F, Nielsen, L N, Smidt, Jelena, Siseklinik, Nakkusosakond, Viard, J-P, Stellbrink, H J, Goethe, J W, Sthoeger, Z M, Monforte, A D’Arminio, Annunziata, Ospedale S Maria, Blokhina, I N, Novogrod, Nizhny, Gatell, J M, Miró, J M, Rodriguez, J M, Laporte, J M, Johnson, A M, Johnson, M A, Morfeldt, Central L, Perri, G Di, Marchetti, G C, Perno, C F, Caputo, S Lo, Capobianchi, M R, Biagio, A Di, Roldan, E Quiros, Santoro, M M, Caro, A Di, Manconi, P E, Moioli, M C, Ridolfo, A L, Martino, F Di, Cattelan, A M, Ursitti, M A, Sulekova, L Fontanelli, Plazzi, M M, Del Vecchio, R Fontana, Giuli, C Di, Orofino, G C, Roger, P M, Braun, D L, Bucher, H C, Günthard, H F, Hirsch, H H, Kouyos, R D, de Tejada, B Martinez, Metzner, K J, Scherrer, A U, Valk, Marc vd, Han, W Min, Saint-Pierre, C H U, Miro, J M, Wasmuth, J C, Vehreschild, J J, McNicholl, I, Williams, E D, Volny-Anne, R Campo Alain, Dedes, Nikos, Mendão, Luis, Jakobsen, M L, Kumar, L Ramesh, Elsing, T W, and null, null
Abstract: Background: Mortality among people with HIV declined with the introduction of combination antiretroviral therapy. We investigated trends over time in all-cause and cause-specific mortality in people with HIV from 1999-2020. Methods: Data were collected from the D:A:D cohort from 1999 through January 2015 and RESPOND from October 2017 through 2020. Age-standardized all-cause and cause-specific mortality rates, classified using Coding Causes of Death in HIV (CoDe), were calculated. Poisson regression models were used to assess mortality trends over time. Results: Among 55716 participants followed for a median of 6 years (IQR 3-11), 5263 participants died (crude mortality rate [MR] 13.7/1000 PYFU; 95%CI 13.4-14.1). Changing patterns of mortality were observed with AIDS as the most common cause of death between 1999- 2009 (n = 952, MR 4.2/1000 PYFU; 95%CI 4.0-4.5) and non-AIDS defining malignancy (NADM) from 2010 -2020 (n = 444, MR 2.8/1000 PYFU; 95%CI 2.5-3.1). In multivariable analysis, all-cause mortality declined over time (adjusted mortality rate ratio [aMRR] 0.97 per year; 95%CI 0.96, 0.98), mostly from 1999 through 2010 (aMRR 0.96 per year; 95%CI 0.95-0.97), and with no decline shown from 2011 through 2020 (aMRR 1·00 per year; 95%CI 0·96-1·05). Mortality due all known causes except NADM also declined over the entire follow-up period. Conclusion: Mortality among people with HIV in the D:A:D and/or RESPOND cohorts decreased between 1999 and 2009 and was stable over the period from 2010 through 2020. The decline in mortality rates was not fully explained by improvements in immunologic-virologic status or other risk factors.
Published: 2024

2. Longitudinal Importance of the Soluble Receptor for Advanced Glycation End-products in COVID-19 Pneumonia

Author: Wick, K.D., primary, Siegel, L., additional, Oldmixon, C., additional, Lundgren, J., additional, Thompson, B.T., additional, Jones, C., additional, Leroux, C., additional, and Matthay, M.A., additional
Published: 2024
Full Text: View/download PDF

3. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

Author: Linner, E., primary, Czuba, T., additional, Gidlöf, O., additional, Lundgren, J., additional, Bollano, E., additional, Hellberg, M., additional, Celik, S., additional, Pimpalwar, N., additional, Rentzsch, P., additional, Martorella, M., additional, Gummessson, A., additional, Melander, O., additional, Albinsson, S., additional, Dellgren, G., additional, Borén, J., additional, Jeppsson, A., additional, Lumbers, T., additional, Shah, S., additional, Nilsson, J., additional, Natarajan, P., additional, Lappalainen, T., additional, Levin, M., additional, Ehrencrona, H., additional, and Smith, J., additional
Published: 2024
Full Text: View/download PDF

4. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

Author: Linner, E., Czuba, T., Gidlof, O., Lundgren, J., Bollano, E., Hellberg, M., Celik, S., Pimpalwar, N., Rentzsch, Philipp, Martorella, M., Gummessson, A., Melander, O., Albinsson, S., Dellgren, G., Boren, J., Jeppsson, A., Lumbers, T., Shah, S., Nilsson, J., Natarajan, P., Lappalainen, T., Levin, M., Ehrencrona, H., Smith, J., Linner, E., Czuba, T., Gidlof, O., Lundgren, J., Bollano, E., Hellberg, M., Celik, S., Pimpalwar, N., Rentzsch, Philipp, Martorella, M., Gummessson, A., Melander, O., Albinsson, S., Dellgren, G., Boren, J., Jeppsson, A., Lumbers, T., Shah, S., Nilsson, J., Natarajan, P., Lappalainen, T., Levin, M., Ehrencrona, H., and Smith, J.
Abstract: QC 20240828
Published: 2024

5. Combination of CO2 electrochemical reduction and biomass gasification for producing methanol : A techno-economic assessment

Author: Li, F., Li, Y., Cao, J., Carvalho, Lara, Lundgren, J., Engvall, K., Zhang, X., Liu, Y., Ji, X., Li, F., Li, Y., Cao, J., Carvalho, Lara, Lundgren, J., Engvall, K., Zhang, X., Liu, Y., and Ji, X.
Abstract: Combining CO2 electrochemical reduction (CO2R) and biomass gasification for producing methanol (CH3OH) is a promising option to increase the carbon efficiency, reduce total production cost (TPC), and realize the utilization of byproducts of CO2R system, but its viability has not been studied. In this work, systematic techno-economic assessments for the processes that combined CO2R to produce CO/syngas/CH3OH with biomass gasification were conducted and compared to stand-alone biomass gasification and CO2R processes, to identify the benefits and analyze the commercialization potential of different pathways under current and future conditions. The results demonstrated that the process that combined biomass gasification with CO2R to CO represents a viable pathway with a competitive TPC of 0.39 €/kg-CH3OH under the current condition. For all the combined cases, electricity usage for CO2R accounts for 36–76% of total operating cost, which plays a key role for TPC. Sensitivity analysis confirmed that the process that combined biomass gasification with CO2R to CO is sensitive to the price of electricity, while both CO2R performance and prices of stack and electricity are important for the processes that combined with CO2R to syngas/CH3OH.
Published: 2024
Full Text: View/download PDF

6. (379) - Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

Author: Czuba, T., Gidlöf, O., Lundgren, J., Bollano, E., Hellberg, M., Celik, S., Pimpalwar, N., Rentzsch, P., Martorella, M., Gummessson, A., Melander, O., Albinsson, S., Dellgren, G., Borén, J., Jeppsson, A., Lumbers, T., Shah, S., Nilsson, J., Natarajan, P., Lappalainen, T., Levin, M., Ehrencrona, H., and Smith, J.
Published: 2024
Full Text: View/download PDF

7. (379) - Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing.

Author: Linner, E., Czuba, T., Gidlöf, O., Lundgren, J., Bollano, E., Hellberg, M., Celik, S., Pimpalwar, N., Rentzsch, P., Martorella, M., Gummessson, A., Melander, O., Albinsson, S., Dellgren, G., Borén, J., Jeppsson, A., Lumbers, T., Shah, S., Nilsson, J., and Natarajan, P.
Subjects: *WHOLE genome sequencing, *HEART failure
Published: 2024
Full Text: View/download PDF

8. Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.

Author: Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, and Reekie J
Subjects: Humans, Male, Female, Adult, Middle Aged, Cohort Studies, Cause of Death, HIV Infections mortality, HIV Infections drug therapy, Anti-HIV Agents therapeutic use
Abstract: Background: Mortality among people with human immunodeficiency virus (HIV) declined with the introduction of combination antiretroviral therapy. We investigated trends in mortality in people with HIV from 1999 through 2020., Methods: Data were collected from the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort between January 1999 through January 2015 and the International Cohort Consortium of Infectious Disease (RESPOND) from October 2017 through December 2020. Age-standardized all-cause and cause-specific mortality rates, classified using Coding Causes of Death in HIV, were calculated. Poisson models were used to assess mortality over time., Results: Among 55 716 participants followed for median 6 years (interquartile range, 3-11), 5263 died (mortality rate [MR], 13.7/1000 person-years of follow-up [PYFU]; 95% confidence interval [CI], 13.4-14.1). Changing mortality was observed: AIDS mortality was most common between 1999-2009 (n = 952; MR, 4.2/1000 PYFU; 95% CI, 4.0-4.5) and non-AIDS-defining malignancy (NADM) between 2010-2020 (n = 444; MR, 2.8/1000 PYFU; 95% CI, 2.5-3.1). In multivariable analysis, all-cause mortality declined (adjusted mortality rate ratio [aMRR], 0.97 per year; 95% CI, .96-.98), mostly 1999-2010 (aMRR, 0.96 per year; 95% CI, .95-.97) but was stable 2011-2020 (aMRR, 1.00 per year; 95% CI, .96-1.05). Mortality due to all known causes except NADM also declined., Conclusions: Mortality among people with HIV in the D:A:D and/or RESPOND cohorts declined between 1999-2009 and was stable over the period 2010-2020. This decline in mortality was not fully explained by improvements in immunologic-virologic status or other risk factors., Competing Interests: Potential conflicts of interest . A. M. reports consulting fees from Eiland and Bonnin. H. F. G. reports honoraria for data and safety monitoring board or advisory board membership from Merck, Gilead Sciences, ViiV Healthcare, GSK, Janssen, Johnson & Johnson, and Novartis; a travel grant from Gilead Sciences; unrestricted research grants from Gilead Sciences; grants or contracts paid to institution from the Swiss National Science Foundation, Swiss HIV Cohort Study, National Institute of Health; and an unrestricted research grant from Gilead Sciences, Yvonne Jacob Foundation. J. J. V. reports personal fees from Merck Sharp & Dohme, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/ Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin, Janssen, NordForsk, Biontech, and APOGEPHA and grants from Merck Sharp & Dohme, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zetrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen, and Network University Medicine. F. W. reports personal fees for attending advisory boards from ViiV Healthcare. A. d’A. M. reports fees for lectures sponsored by ViiV, Gilead, and Pfizer and projects sponsored (to institution) by ViiV, Gilead, and Merck Sharpe & Dohme. V. S. reports CME education fees from Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. C. C. reports an unrestricted Nordic Fellowship Grant from Gilead Sciences Nordic; honoraria from GSK and ViiV, Gilead Sciences, and Merck Sharp & Dohme (paid to institution), and has participated on an advisory board for GSK, ViiV and Gilead Sciences (paid to institution). P. S. reports honoraria and/or speaking fees from Gilead, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, and ViiV Healthcare and a research grant from ViiV Healthcare, all outside of the submitted work. A. C. reports consulting fees from Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare; honoraria for presentations from Gilead Sciences and ViiV Healthcare; support for travel to advisory board and to study investigator meetings from Merck Sharp & Dohme; and receipt of study medication and supplies from Merck Sharp & Dohme. K. P. reports unrestricted research funding made to institution by Gilead Australia and ViiV Healthcare Australia. F. Bonnet reports grants from Gilead and ViiV Healthcare and honoraria from Gilead, ViiV Healthcare, and Merck Sharp & Dohme. S. D. W. reports payments from the D:A:D and RESPOND studies paid to institution. J. G. is an employee of Gilead Sciences. V. V. is an employee of ViiV Healthcare. L. Y. is an employee of Merck Sharp & Dohme. C. S. reports honoraria for preparation of educational materials from Gilead Sciences and honoraria for speaking and preparation of educational materials from ViiV Healthcare. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Published: 2024
Full Text: View/download PDF

9. Management of Post-transplant Infections in Collaborating Hospitals (MATCH) Programme: a prospective cohort of all transplant recipients at Copenhagen University Hospital-Rigshospitalet, Denmark.

Author: Esmann FVL, Zahid S, Moestrup KS, Normand N, Matthews C, Gustafsson F, Sengeløv H, Perch M, Schultz NA, Sørensen SS, Hansen JM, Christensen VB, Murray DD, Lundgren J, Crone CG, and Helleberg M
Subjects: Humans, Denmark, Prospective Studies, Female, Male, Adult, Middle Aged, Organ Transplantation adverse effects, Registries, Hospitals, University, Adolescent, Young Adult, Virus Diseases prevention & control, Aged, Child, Postoperative Complications prevention & control, Postoperative Complications epidemiology, Hematopoietic Stem Cell Transplantation, Transplant Recipients statistics & numerical data
Abstract: Purpose: The Management of Post-transplant Infections in Collaborating Hospitals (MATCH) programme, initiated in 2011 and still ongoing, was created to 1) optimise the implementation of existing preventive strategies against viral infections in solid organ transplant (SOT) recipients and allogenic haematopoietic stem-cell transplant (HSCT) recipients and 2) advance research in the field of transplantation by collecting data from a multitude of sources., Participants: All SOT and HSCT recipients at Copenhagen University Hospital, Rigshospitalet, are followed in MATCH. By February 2021, a total of 1192 HSCT recipients and 2039 SOT recipients have been included. Participants are followed life long. An automated electronic data capture system retrieves prospective data from nationwide registries. Data from the years prior to transplantation are also collected., Findings to Date: Data entries before and after transplantation include the following: biochemistry: 13 995 222 and 26 127 817; microbiology, cultures: 242 023 and 410 558; other microbiological analyses: 265 007 and 566 402; and pathology: 170 884 and 200 394. There are genomic data on 2431 transplant recipients, whole blood biobank samples from 1003 transplant recipients and faeces biobank samples from 207 HSCT recipients. Clinical data collected in MATCH have contributed to 50 scientific papers published in peer-reviewed journals and have demonstrated success in reducing cytomegalovirus disease in SOT recipients. The programme has established international collaborations with the Swiss Transplant Cohort Study and the lung transplant cohort at Toronto General Hospital., Future Plans: Enrolment into MATCH is ongoing with no planned end date for enrolment or follow-up. MATCH will continue to provide high-quality data on transplant recipients and expand and strengthen international collaborations., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Published: 2024
Full Text: View/download PDF

10. Changing from disease-centred to person-centred - Swedish dental hygienists' views on a theory-based behavioural intervention for improved oral hygiene among adolescents.

Author: Dimenäs SL, Jönsson B, Lundin M, Lundgren J, and Abrahamsson KH
Subjects: Humans, Sweden, Adolescent, Female, Male, Interviews as Topic, Adult, Qualitative Research, Dental Hygienists psychology, Oral Hygiene, Attitude of Health Personnel, Patient-Centered Care
Abstract: Objectives: To explore dental hygienists' (DHs') views on (i) a person-centred, theory-based, behavioural intervention for improving oral hygiene among adolescents and (ii) professional and organizational factors to consider in the implementation of such an intervention in daily dental practice., Methods: Semi-structured interviews were conducted with 13 DHs who had applied the person-centred, theory-based, behavioural intervention directed at adolescents with poor oral hygiene in a field study within the Public Dental Service, Region Västra Götaland, Sweden. The interviews were audio-taped, transcribed verbatim and analysed using qualitative content analysis., Results: The main theme 'From individual experts to partners - DHs changing direction from a disease-centred towards a person-centred approach' illustrated a changed professional approach among DHs, from exerting their roles as experts to encouraging partnership in treatment by supporting the adolescents in taking health behavioural decisions and responsibility for their oral health. The DHs considered the changed approach as challenging, but also more enjoyable, compared to conventional information/instruction. Adequate knowledge and skills, personal interest and willingness for a change as well as support from colleagues and clinic management were identified as prerequisites for implementing the person-centred, theory-based, behavioural intervention in daily practice, while the expenditure of time needed in relation to economic demands in care were seen as barriers., Conclusions: The findings elucidate that DHs considered the application of a person-centred, theory-based, behavioural intervention to be challenging but also enjoyable. For such an intervention to be implemented in daily practice, prerequisites and barriers need to be considered on both personal/professional and organizational levels., (© 2024 The Authors. International Journal of Dental Hygiene published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

11. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study.

Author: Sejdic A, Hartling HJ, Gitz Holler J, Klingen Gjærde L, Matovu Dungu A, Engel Møller ME, Svanberg Teglgaard R, Utoft Niemann CU, Brooks PT, Mogensen TH, Weis N, Podlekareva D, Baum Jørgensen ML, Ortved Gang A, Stampe Hersby D, Hald A, Dam Nielsen S, Lebech AM, Helleberg M, Lundgren J, Træholt Franck K, Fischer TK, Barrella Harboe Z, Marquart HV, Rye Ostrowski S, and Lindegaard B
Subjects: Humans, Male, Pilot Projects, Female, Middle Aged, Aged, Cohort Studies, Adult, Hospitalization, Denmark, Immunophenotyping, B-Lymphocytes immunology, Overweight immunology, COVID-19 immunology, Body Mass Index, Obesity immunology, Obesity complications, SARS-CoV-2 immunology, Cytokines immunology, Cytokines blood
Abstract: Introduction: Overweight and obesity are linked to increased hospitalization and mortality in COVID-19 patients. This study aimed to characterize induced immune responses and deep immune cell profiles stratified by BMI in hospitalized COVID-19 patients., Methods and Results: This observational multicenter cohort pilot study included 122 adult patients with PCR-confirmed COVID-19 in Denmark, stratified by BMI (normal weight, overweight, obese). Inflammation was assessed using TruCulture® and immune cell profiles by flow cytometry with a customized antibody panel (DuraClone®). Patients with obesity had a more pro-inflammatory phenotype with increased TNF-α, IL-8, IL-17, and IL-10 levels post-T cell stimulation, and altered B cell profiles. Patients with obesity showed higher concentrations of naïve, transitional, and non-isotype switched memory B cells, and plasmablasts compared to normal weight patients and healthy controls., Conclusions: Obesity in hospitalized COVID-19 patients may correlate with elevated pro-inflammatory cytokines, anti-inflammatory IL-10, and increased B cell subset activation, highlighting the need for further studies., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

12. Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.

Author: Juhl AK, Dietz LL, Søgaard OS, Reekie J, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Jensen TØ, Olesen R, Iversen K, Fogh K, Bodilsen J, Madsen LW, Lindvig SO, Raben D, Andersen SD, Hvidt AK, Andreasen SR, Baerends EAM, Lundgren J, Østergaard L, and Tolstrup M
Subjects: Humans, Male, Prospective Studies, Female, Middle Aged, Adult, Longitudinal Studies, Immunity, Cellular, Aged, Vaccination, Immunization, Secondary, T-Lymphocytes immunology, Young Adult, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Antibodies, Viral blood, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, CD8-Positive T-Lymphocytes immunology, Spike Glycoprotein, Coronavirus immunology, CD4-Positive T-Lymphocytes immunology
Abstract: Background: Within a year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, vaccines inducing a robust humoral and cellular immune response were implemented worldwide. However, emergence of novel variants and waning vaccine-induced immunity led to implementation of additional vaccine boosters., Methods: This prospective study evaluated the temporal profile of cellular and serological responses in a cohort of 639 SARS-CoV-2-vaccinated participants, of whom a large proportion experienced a SARS-CoV-2 infection. All participants were infection naïve at the time of their first vaccine dose. Proportions of SARS-CoV-2 spike-specific T cells were determined after each vaccine dose using the activation-induced marker assay, while levels of circulating SARS-CoV-2 antibodies were determined by the Meso Scale serology assay., Results: We found a significant increase in SARS-CoV-2 spike-specific CD4+ and CD8+ T-cell responses following the third dose of a SARS-CoV-2 messenger RNA vaccine as well as enhanced CD8+ T-cell responses after the fourth dose. Furthermore, increased age was associated with a poorer response. Finally, we observed that SARS-CoV-2 infection boosts both the cellular and humoral immune response, relative to vaccine-induced immunity alone., Conclusions: Our findings highlight the boosting effect on T-cell immunity of repeated vaccine administration. The combination of multiple vaccine doses and SARS-CoV-2 infections maintains population T-cell immunity, although with reduced levels in the elderly., Competing Interests: Potential conflicts of interest . T. B. reports the following grants from the past 36 months: unrestricted grant to his institution from Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, Kai Foundation, Erik and Susanna Olesen’s Charitable Fund; unrestricted grant to his institution, principal investigator [PI]/clinical trial, advisory board from Pfizer, MSD, GSK, and Gilead Sciences; and grant for PI/clinical trial from Boehringer Ingelheim, Roche, Novartis, Kancera AB, Janssen, and AstraZeneca. T. B. is board member in Pentabase; serves on advisory boards for Janssen and AstraZeneca; and reports receiving payment or honoraria for lectures at GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, AbbVie, and AstraZeneca. L. W. M. reports receiving travel support from AbbVie in September 2023. N. B. S. reports receiving funding from Danish Ministry of Health for the manuscript and consulting fees on study regarding respiratory syncytial virus from Pfizer and serving as PI in clinical studies sponsored by Pfizer, Bavarian Nordic, Moderna, and AstraZeneca. O. S. S. reports receiving funding from Danish Ministry of Health for the manuscript and consulting fees from UNION therapeutics and participation on a data and safety monitoring board or advisory board with Immunocore, ViiV Healthcare, and Gilead. M.T. reports funding from Danish Ministry of Health for the manuscript. All other authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Published: 2024
Full Text: View/download PDF

13. Impact of baseline SARS-CoV-2 load in plasma and upper airways on the incidence of acute extrapulmonary complications of COVID-19: a multicentric, prospective, cohort study.

Author: Jensen TO, Harper K, Gupta S, Liu ST, Dharan NJ, Baker JV, Pett SL, Shaw-Saliba K, Esmail A, Ho MQ, Almasri E, Dewar RL, Lundgren J, and Vock DM
Abstract: Background: Extrapulmonary complications (EPCs) are common in patients hospitalized for COVID-19, but data on their clinical consequences and association with viral replication and systemic viral dissemination is lacking., Methods: Patients hospitalized for COVID-19 and enrolled in the TICO (Therapeutics for Inpatients with COVID-19) platform trial at 114 international sites between August 2020 and November 2021 were included in a prospective cohort study. We categorized EPCs into 39 event types within 9 categories and estimated their frequency through day 28 and their association with clinical outcomes through day 90. We analyzed the association between baseline viral burden (plasma nucleocapsid antigen [N-Ag] and upper airway viral load [VL]) and EPCs, adjusting for other baseline factors., Results: 2,625 trial participants were included in the study. The median age was 57 years (IQR 46-68), 57.7% were male, and 537 (20.5%) had at least one EPC. EPCs were associated with higher day-90 all-cause mortality (HR 9.6, 95% CI 7.3, 12.7) after adjustment for other risk factors. The risk of EPCs increased with increasing baseline plasma N-Ag (HR 1.21 per log10 ng/L increase, 95% CI 1.09, 1.34), and upper airway VL (HR 1.12 per log10 copies/mL increase, 95% CI 1.04, 1.19), after adjusting for comorbidities, disease severity, inflammatory markers, and other baseline factors. Trial treatment allocation had no effect on EPC risk., Conclusions: Systemic viral dissemination as evidenced by high plasma N-Ag and high respiratory viral burden are associated with development of EPCs in COVID-19, which in turn are associated with higher 90-day mortality., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Published: 2024
Full Text: View/download PDF

14. Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19.

Author: Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga A, Jensen TO, Jain MK, Kalomenidis I, Kim K, Lallemand P, Lindegaard B, Menon A, Ognenovska K, Poulakou G, Thorup Røge B, Rogers AJ, Shaw-Saliba K, Sandkovsky U, Trautner BW, Vasudeva SS, Vekstein A, Viens K, Wyncoll J, DuChateau B, Zhang Z, Wu S, Babiker AG, Davey V, Gelijns A, Higgs E, Kan V, Lundgren J, Matthews GV, and Lane HC
Abstract: Background: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests., Methods: COVID-19 inpatients were recruited to evaluate 2 POC tests: LumiraDX and RightSign. Ease of use data was collected. Blood was also collected for centralized testing using established antibody assays (GenScript cPass). A nested case-control study assessed if POC tests conducted on stored specimens were predictive of time to sustained recovery, mortality, and a composite safety outcome., Results: While both POC tests exhibited moderate agreement with the GenScript assay (both agreeing with 89% of antibody determinations), they were significantly different from the GenScript assay. Treating the GenScript assay as the gold standard, the LumiraDX assay had 99.5% sensitivity and 58.1% specificity while the RightSign assay had 89.5% sensitivity and 84.0% specificity. The LumiraDX assay frequently gave indeterminant results. Both tests were significantly associated with clinical outcomes., Conclusions: Although both POC tests deviated moderately from the GenScript assay, they predicted outcomes of interest. The RightSign test was easier to use and was more likely to detect those lacking antibody compared to the LumiraDX test treating GenScript as the gold standard., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Published: 2024
Full Text: View/download PDF

15. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.

Author: Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, and Reilly C
Subjects: Humans, Female, Male, Middle Aged, Aged, Adult, RNA, Viral blood, COVID-19 Drug Treatment, Antibodies, Viral blood, Antigens, Viral blood, COVID-19 mortality, SARS-CoV-2, Hospitalization, Interleukin-6 blood, Antiviral Agents therapeutic use
Abstract: Background: Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus and host response factors were associated with mortality risk among participants in Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) trials., Methods: A secondary analysis of 2625 adults hospitalized for acute SARS-CoV-2 infection randomized to 1 of 5 antiviral products or matched placebo in 114 centers on 4 continents. Uniform, site-level collection of participant baseline clinical variables was performed. Research laboratories assayed baseline upper respiratory swabs for SARS-CoV-2 viral RNA and plasma for anti-SARS-CoV-2 antibodies, SARS-CoV-2 nucleocapsid antigen (viral Ag), and interleukin-6 (IL-6). Associations between factors and time to mortality by 90 days were assessed using univariate and multivariable Cox proportional hazards models., Results: Viral Ag ≥4500 ng/L (vs <200 ng/L; adjusted hazard ratio [aHR], 2.07; 1.29-3.34), viral RNA (<35 000 copies/mL [aHR, 2.42; 1.09-5.34], ≥35 000 copies/mL [aHR, 2.84; 1.29-6.28], vs below detection), respiratory support (<4 L O2 [aHR, 1.84; 1.06-3.22]; ≥4 L O2 [aHR, 4.41; 2.63-7.39], or noninvasive ventilation/high-flow nasal cannula [aHR, 11.30; 6.46-19.75] vs no oxygen), renal impairment (aHR, 1.77; 1.29-2.42), and IL-6 >5.8 ng/L (aHR, 2.54 [1.74-3.70] vs ≤5.8 ng/L) were significantly associated with mortality risk in final adjusted analyses. Viral Ag, viral RNA, and IL-6 were not measured in real-time., Conclusions: Baseline virus-specific, clinical, and biological variables are strongly associated with mortality risk within 90 days, revealing potential pathogen and host-response therapeutic targets for acute COVID-19 disease., Competing Interests: Potential conflicts of interest. N. R. A. reports support for attending meetings and/or travel to their institution from the National Institutes of Health (NIH). D. L. B. reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and participation on a Data Safety Monitoring Board (DSMB) or Advisory Board with Pfizer, Gilead, MSD, and ViiV; and support for attending meetings and/or travel from ViiV and Gilead. M. K. J. reports a grant to their institution from Gilead Sciences and a contract for a clinical trial to their institution from Regeneron; and a role on the HIV MA Board of Directors. J. P. H. reports consulting fees to the author from Pfizer, MSD, Menarini, Angelini, Zambon, and Tillots; payment or honoraria payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events to their institution and the author from Pfizer and to the author from MSD and Angelini; support for attending meetings and/or travel from MSD and Pfizer; and paid participation as a DSMB member for a TFT Pharmaceuticals clinical trial. K. K. reports grants or contracts to their institution from the NIH, COVID Vaccine Prevention Network, (NIH), Regeneron, Abbott, Pfizer, Romark, and Raisonance; royalties or licenses to book author for Elsevier; consulting fees to the author from Regeneron; payment for expert testimony to the author from the State of Florida; support for travel from Sanford Guide, Burroughs Wellcome Fund, ParaFrap, and the Infectious Diseases Society of America (IDSA) Board of Directors; patents planned, issued, or pending to University of South Florida (USF) F and USF faculty from 3D swabs; leadership or a fiduciary role on the Sanford Guide, Burroughs Wellcome Fund, IDSA board, and ParaFrap; and personal stocks from Gilead. S. L. P. reports grants paid to the University College London, which are completely separate from this work, with Medical Research Council, United Kingdom Research and Innovation, The European and Developing Countries Clinical Trial Partnership, Janssen-Cilag, Gilead Sciences, and ViiV Healthcare; participation as member of the DSMB for the TIPAL trial (The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole: a randomized placebo-controlled multicenter clinical trial). This is an academic trial funded in the United Kingdom by the National Institute for Health and Care Research (NIHR), UK. C. R. reports grants or contracts from NIH and participation on a DSMB or Advisory Board from Mayo Clinic and NIH. U. S. reports research grants or contracts from ViiV Healthcare and AstraZeneca; consulting fees from Shionogi, Paratek, ViiV, and Pfizer; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Shionogi, Pfizer, and Paratek. B. W. T. reports grants or contracts from Veterans Affairs (VA) Health Services and Development Service Center for Innovations in Quality, Effectiveness, and Safety (13-413), Agency for Healthcare Research and Quality (AHRQ), VA Rehabilitation Research and Development, and Peptilogics; consulting fees from Phiogen; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the George Washington ID Board Review Course, the Warren Alpert Medical School of Brown University. A. A. G. reports grants to their institution from Centers for Disease Control, Department of Defense, Faron Pharmaceuticals, and AbbVie; participation on a DSMB or Advisory Board from NIH; and a role on the Scientific Advisory Board from Biomeme. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2024
Full Text: View/download PDF

16. E-therapists' views on the acceptability and feasibility of an internet-administered, guided, low-intensity cognitive behavioural therapy intervention for parents of children treated for cancer: A qualitative study.

Author: Reuther C, Lundgren J, Gottvall M, Ljungberg J, Woodford J, and von Essen L
Abstract: Background: Childhood cancer treatment completion can be a period of vulnerability for parents and is associated with mental health difficulties such as depression and anxiety. We developed an internet-administered, guided, low-intensity cognitive behavioural therapy-based self-help intervention (EJDeR) for parents delivered on the U-CARE-portal (Portal). The acceptability and feasibility of EJDeR and study procedures were examined using a single-arm feasibility trial (ENGAGE). Results indicated that EJDeR and ENGAGE study procedures are acceptable and feasible, however, a need for clinical and technical modifications to EJDeR and refinements to ENGAGE study procedures was identified., Objectives: This study aimed to explore the acceptability and feasibility of EJDeR and ENGAGE study procedures from the perspective of e-therapists to inform clinical and technical modifications to EJDeR and refinements to study procedures prior to progression to a superiority randomised controlled trial., Methods: We conducted semi-structured interviews with 10 e-therapists. Data were analysed using manifest content analysis., Results: We identified three categories relating to the acceptability and feasibility of EJDeR: (a) Support to e-therapists (subcategories: Clinical supervision and Technical difficulties); (b) Guidance to parents (subcategories: Support protocols and Synchronous communication); and (c) Content (subcategories: Relevancy of the intervention and Pacing of the intervention). We identified four categories relating to the acceptability and feasibility of study procedures: (a) Recruitment and training of e-therapists (subcategories: Definition of the role and Training program); (b) Retention of parents (subcategories: Parent suitability and screening and Frequency of weekly Portal assessments); (c) Retention of e-therapists (subcategories: Administrative requirements and Communication with the research team); and (d) The Portal ., Conclusions: EJDeR and study procedures were considered acceptable and feasible, however, clinical and technical modifications and refinements to study procedures were suggested to enhance acceptability and feasibility. Results may also inform implementation considerations for both EJDeR and other similar digital psychological interventions., Trial Registration Number: ISRCTN 57233429., Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2024.)
Published: 2024
Full Text: View/download PDF

17. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.

Author: Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, and Ko ER
Subjects: Humans, Prospective Studies, Male, Female, Middle Aged, Aged, Fibrin Fibrinogen Degradation Products analysis, Antibodies, Monoclonal, Humanized therapeutic use, Interleukin-6 blood, C-Reactive Protein analysis, C-Reactive Protein metabolism, Pandemics, Coronavirus Infections immunology, Coronavirus Infections blood, Coronavirus Infections mortality, Coronavirus Infections drug therapy, Coronavirus Infections virology, Pneumonia, Viral immunology, Pneumonia, Viral blood, Pneumonia, Viral mortality, Pneumonia, Viral drug therapy, Pneumonia, Viral virology, Treatment Outcome, COVID-19 immunology, COVID-19 mortality, COVID-19 blood, Biomarkers blood, SARS-CoV-2 immunology, Hospitalization statistics & numerical data
Abstract: Background: Serial measurement of virological and immunological biomarkers in patients admitted to hospital with COVID-19 can give valuable insight into the pathogenic roles of viral replication and immune dysregulation. We aimed to characterise biomarker trajectories and their associations with clinical outcomes., Methods: In this international, prospective cohort study, patients admitted to hospital with COVID-19 and enrolled in the Therapeutics for Inpatients with COVID-19 platform trial within the Accelerating COVID-19 Therapeutic Interventions and Vaccines programme between Aug 5, 2020 and Sept 30, 2021 were included. Participants were included from 108 sites in Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, the UK, and the USA, and randomised to placebo or one of four neutralising monoclonal antibodies: bamlanivimab (Aug 5 to Oct 13, 2020), sotrovimab (Dec 16, 2020, to March 1, 2021), amubarvimab-romlusevimab (Dec 16, 2020, to March 1, 2021), and tixagevimab-cilgavimab (Feb 10 to Sept 30, 2021). This trial included an analysis of 2149 participants with plasma nucleocapsid antigen, anti-nucleocapsid antibody, C-reactive protein (CRP), IL-6, and D-dimer measured at baseline and day 1, day 3, and day 5 of enrolment. Day-90 follow-up status was available for 1790 participants. Biomarker trajectories were evaluated for associations with baseline characteristics, a 7-day pulmonary ordinal outcome, 90-day mortality, and 90-day rate of sustained recovery., Findings: The study included 2149 participants. Participant median age was 57 years (IQR 46-68), 1246 (58·0%) of 2149 participants were male and 903 (42·0%) were female; 1792 (83·4%) had at least one comorbidity, and 1764 (82·1%) were unvaccinated. Mortality to day 90 was 172 (8·0%) of 2149 and 189 (8·8%) participants had sustained recovery. A pattern of less favourable trajectories of low anti-nucleocapsid antibody, high plasma nucleocapsid antigen, and high inflammatory markers over the first 5 days was observed for high-risk baseline clinical characteristics or factors related to SARS-CoV-2 infection. For example, participants with chronic kidney disease demonstrated plasma nucleocapsid antigen 424% higher (95% CI 319-559), CRP 174% higher (150-202), IL-6 173% higher (144-208), D-dimer 149% higher (134-165), and anti-nucleocapsid antibody 39% lower (60-18) to day 5 than those without chronic kidney disease. Participants in the highest quartile for plasma nucleocapsid antigen, CRP, and IL-6 at baseline and day 5 had worse clinical outcomes, including 90-day all-cause mortality (plasma nucleocapsid antigen hazard ratio (HR) 4·50 (95% CI 3·29-6·15), CRP HR 3·37 (2·30-4·94), and IL-6 HR 5·67 (4·12-7·80). This risk persisted for plasma nucleocapsid antigen and CRP after adjustment for baseline biomarker values and other baseline factors., Interpretation: Patients admitted to hospital with less favourable 5-day biomarker trajectories had worse prognosis, suggesting that persistent viral burden might drive inflammation in the pathogenesis of COVID-19, identifying patients that might benefit from escalation of antiviral or anti-inflammatory treatment., Funding: US National Institutes of Health., Competing Interests: Declaration of interests ALG reports receiving institutional funding from Novavax, institutional partnership with AstraZeneca, and being personally named as inventor on a patent used by AstraZeneca. DDM reports receiving grants from the Danish National Research Foundation. DL reports participation in a study funded by Gilead with no salary support. EM reports payments to his institution received from SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Pfizer, Chemic Labs and KODA Therapeutics, and Cidara, and payment for participating in an advisory board for Basilea. KW reports honorarium for Acute Respiratory Distress Syndrome (ARDS) International Conference in 2023, and travel support from University of California San Francisco. MAM reports institutional funding by the US Department of Defence, Roche-Genetech, and Quantum Health, and personal consulting fees from Gilead, Novartis, and Johnson & Johnson. MKJ reports grants received from Regeneron, Laurent, and Gilead, honoraria from Gilead, and a leadership role with the HIV Medicine Association Board of Directors. PC reports consulting fees from Eli Lilly and Regeneron. All other authors declare no competing interests. All authors were not precluded from accessing data in the study., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

18. The effects of internet-based cognitive behaviour therapy for depression in cardiovascular disease on symptoms of anxiety: a secondary analysis of a randomized trial.

Author: Westas M, Mourad G, Andersson G, Lundgren J, and Johansson P
Subjects: Humans, Female, Male, Middle Aged, Aged, Internet, Depression therapy, Depression psychology, Treatment Outcome, Adult, Internet-Based Intervention, Anxiety therapy, Anxiety psychology, Anxiety etiology, Follow-Up Studies, Cognitive Behavioral Therapy methods, Cardiovascular Diseases psychology, Cardiovascular Diseases therapy
Abstract: Aims: The aims of this study were to evaluate: (i) the short- and long-term effects of the internet-based cognitive behaviour (iCBT) programme on symptoms of distress and fear disorder in cardiovascular disease (CVD) patients, and (ii) the association between changes in depression and changes in symptoms of distress and fear disorder from baseline to 12-month follow-up., Methods and Results: Secondary analysis of data collected in a randomized controlled study evaluating the effects on depression of an iCBT programme compared to an online discussion forum (ODF) in CVD patients (n = 144). Data were collected at baseline, at post-intervention (9 weeks), and at 6- and 12-month follow-ups.The results showed that symptoms of distress disorder were statistically significantly more reduced in the iCBT group than in the ODF group. For symptoms of the fear disorder, no differences were found except for avoidance, which showed a statistically significant reduction in the iCBT group. The long-term analysis in the iCBT group showed that CAQ total score and fear decreased from baseline to 6- and 12-month follow-ups, respectively. Avoidance and attention both decreased statistically significantly from baseline to post-intervention, but not between post-intervention and 12-month follow-up., Conclusion: The results suggest that the iCBT programme targeted depression in CVD patients successfully reduced symptoms of distress disorder and to a lesser extent symptoms of fear disorder. Change in depression was more strongly associated with a change in distress than a change in fear disorder., Registration: ClinicalTrials.gov: NCT02778074., Competing Interests: Conflicts of interest: None of the authors have any conflicts of interest or financial ties to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Published: 2024
Full Text: View/download PDF

19. Cervical Spondylosis Diagnosis Based on Convolutional Neural Network with X-ray Images.

Author: Xie Y, Nie Y, Lundgren J, Yang M, Zhang Y, and Chen Z
Subjects: Humans, Cervical Vertebrae diagnostic imaging, X-Rays, Image Processing, Computer-Assisted methods, Spondylosis diagnostic imaging, Neural Networks, Computer, Deep Learning
Abstract: The increase in Cervical Spondylosis cases and the expansion of the affected demographic to younger patients have escalated the demand for X-ray screening. Challenges include variability in imaging technology, differences in equipment specifications, and the diverse experience levels of clinicians, which collectively hinder diagnostic accuracy. In response, a deep learning approach utilizing a ResNet-34 convolutional neural network has been developed. This model, trained on a comprehensive dataset of 1235 cervical spine X-ray images representing a wide range of projection angles, aims to mitigate these issues by providing a robust tool for diagnosis. Validation of the model was performed on an independent set of 136 X-ray images, also varied in projection angles, to ensure its efficacy across diverse clinical scenarios. The model achieved a classification accuracy of 89.7%, significantly outperforming the traditional manual diagnostic approach, which has an accuracy of 68.3%. This advancement demonstrates the viability of deep learning models to not only complement but enhance the diagnostic capabilities of clinicians in identifying Cervical Spondylosis, offering a promising avenue for improving diagnostic accuracy and efficiency in clinical settings.
Published: 2024
Full Text: View/download PDF

20. The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants.

Author: Mørup SB, Leung P, Reilly C, Sherman BT, Chang W, Milojevic M, Milinkovic A, Liappis A, Borgwardt L, Petoumenos K, Paredes R, Mistry SS, MacPherson CR, Lundgren J, Helleberg M, Reekie J, and Murray DD
Subjects: Humans, Male, Female, Adult, Genotype, Middle Aged, Receptor, Interferon alpha-beta genetics, Cohort Studies, Disease Progression, CD4 Lymphocyte Count, HIV Infections virology, HIV Infections genetics, HIV Infections immunology, HIV-1 genetics, Polymorphism, Single Nucleotide, Viral Load, Interferon Type I genetics
Abstract: Background: Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL)., Methods: Two cohorts of antiretroviral (ART) naïve participants living with HIV (PLWH) with either early (START) or advanced infection (FIRST) were analysed separately. Type 1 IFN genes (n = 17) and receptor subunits (IFNAR1, IFNAR2) were examined for both cumulated type 1 IFN pathway analysis and individual gene analysis. SKAT-O was applied to detect associations between the genotype and HIV-1 study entry viral load (log10 transformed) as a proxy for set point VL; P-values were corrected using Bonferroni (P < 0.0025)., Results: The analyses among those with early infection included 2429 individuals from five continents. The median study entry HIV VL was 14,623 (IQR 3460-45100) copies/mL. Across 673 SNPs within 19 type 1 IFN genes, no significant association with study entry VL was detected. Conversely, examining individual genes in START showed a borderline significant association between IFNW1, and study entry VL (P = 0.0025). This significance remained after separate adjustments for age, CD4 + T-cell count, CD4 + /CD8 + T-cell ratio and recent infection. When controlling for population structure using linear mixed effects models (LME), in addition to principal components used in the main model, this was no longer significant (p = 0.0244). In subgroup analyses stratified by geographical region, the association between IFNW1 and study entry VL was only observed among African participants, although, the association was not significant when controlling for population structure using LME. Of the 17 SNPs within the IFNW1 region, only rs79876898 (A > G) was associated with study entry VL (p = 0.0020, beta = 0.32; G associated with higher study entry VL than A) in single SNP association analyses. The findings were not reproduced in FIRST participants., Conclusion: Across 19 type 1 IFN genes, only IFNW1 was associated with HIV-1 study entry VL in a cohort of ART-naïve individuals in early stages of their infection, however, this was no longer significant in sensitivity analyses that controlled for population structures using LME., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

21. Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.

Author: Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, and Ko ER
Subjects: Humans, SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Monoclonal therapeutic use, Biomarkers, COVID-19
Abstract: Background: Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood., Methods: Participants enrolled in the Therapeutics for Inpatients with COVID-19 trials were randomized to nmAb versus placebo. Longitudinal differences between treatment and placebo groups in levels of plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein, interleukin-6, and D-dimer at enrollment, day 1, 3, and 5 were estimated using linear mixed models. A 7-point pulmonary ordinal scale assessed at day 5 was compared using proportional odds models., Results: Analysis included 2149 participants enrolled between August 2020 and September 2021. Treatment resulted in 20% lower levels of plasma N-Ag compared with placebo (95% confidence interval, 12%-27%; P < .001), and a steeper rate of decline through the first 5 days (P < .001). The treatment difference did not vary between subgroups, and no difference was observed in trajectories of other biomarkers or the day 5 pulmonary ordinal scale., Conclusions: Our study suggests that nmAb has an antiviral effect assessed by plasma N-Ag among hospitalized patients with COVID-19, with no blunting of the endogenous anti-nucleocapsid antibody response. No effect on systemic inflammation or day 5 clinical status was observed., Clinical Trials Registration: NCT04501978., Competing Interests: Potential conflicts of interest. A. L. G. reports receiving institutional funding from Novavax, insititutaional partnership with Astra Zeneca, and reports being personally named as inventor on a patent used by Astra Zeneca. D. D. M. reports receiving grant from the Danish National research Foundation. E. M. reports payments to his institution received from SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Pfizer, Chemic Labs/KODA Therapeutics, Cidara, and Leidos Biomedical Research Inc; E. M. also reports being on an advisory board for Basilea. K. W. reports receiving a honorarium for international ARDS conference and travel support from UCSF. M. A. reports a grant from NINDS. M. A. M. reports institutional grants from NHLBI/NIAID, the department of defence, California Institute of Regeneration, Roche-Genentech, and Quantum Health. M. A. M. has also received personal consulting fees from Novartis, Pliant Therapeutics, Johnson and Johnson, Gilead, and Citius Pharmaceuticals. M. K. J. reports institutional grants from Gilead, Laurent, and Regeneron; personal consulting fees from Gilead; and personal honoraria from Cooper Clinic. S. T. is funded by grants from the Australian Medical Foundation and New South Wales Health. The remaining authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Published: 2024
Full Text: View/download PDF

22. Correlation of mitochondrial respiration in platelets, peripheral blood mononuclear cells and muscle fibers.

Author: Westerlund E, Marelsson SE, Karlsson M, Sjövall F, Chamkha I, Åsander Frostner E, Lundgren J, Fellman V, Eklund EA, Steding-Ehrenborg K, Darin N, Paul G, Hansson MJ, Ehinger JK, and Elmér E
Abstract: There is a growing interest for the possibility of using peripheral blood cells (including platelets) as markers for mitochondrial function in less accessible tissues. Only a few studies have examined the correlation between respiration in blood and muscle tissue, with small sample sizes and conflicting results. This study investigated the correlation of mitochondrial respiration within and across tissues. Additional analyses were performed to elucidate which blood cell type would be most useful for assessing systemic mitochondrial function. There was a significant but weak within tissue correlation between platelets and peripheral blood mononuclear cells (PBMCs). Neither PBMCs nor platelet respiration correlated significantly with muscle respiration. Muscle fibers from a group of athletes had higher mass-specific respiration, due to higher mitochondrial content than non-athlete controls, but this finding was not replicated in either of the blood cell types. In a group of patients with primary mitochondrial diseases, there were significant differences in blood cell respiration compared to healthy controls, particularly in platelets. Platelet respiration generally correlated better with the citrate synthase activity of each sample, in comparison to PBMCs. In conclusion, this study does not support the theory that blood cells can be used as accurate biomarkers to detect minor alterations in muscle respiration. However, in some instances, pronounced mitochondrial abnormalities might be reflected across tissues and detectable in blood cells, with more promising findings for platelets than PBMCs., Competing Interests: Imen Chamkha, Johannes K. Ehinger, Eskil Elmér, Magnus J. Hansson, Michael Karlsson, and Eleonor Åsander Frostner have equity interests in, and/or have received salary support and/or travel reimbursements and/or grants from Abliva AB (formerly NeuroVive Pharmaceutical AB), a public company developing pharmaceuticals in the field of mitochondrial medicine. The other authors declare no financial or commercial conflict of interest., (© 2024 The Authors.)
Published: 2024
Full Text: View/download PDF

23. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.

Author: Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, Papanicolaou GA, Pereira MR, Wu JJ, Murray RA, Buss NE, and Fournier M
Subjects: Humans, Antiviral Agents therapeutic use, Antiviral Agents pharmacology, Benzimidazoles therapeutic use, Cytomegalovirus genetics, DNA, Drug Resistance, Viral genetics, Ganciclovir therapeutic use, Mutation, Phosphotransferases (Alcohol Group Acceptor) genetics, Transplant Recipients, Cytomegalovirus Infections drug therapy, Dichlororibofuranosylbenzimidazole analogs & derivatives, Ribonucleosides therapeutic use
Abstract: Background: This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders)., Methods: Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54, and UL27., Results: At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. Among them, 63% (maribavir) and 21% (IAT) were treatment responders. Detected baseline maribavir resistance mutations were UL27 L193F (n = 1) and UL97 F342Y (n = 3). Posttreatment, emergent maribavir resistance mutations were detected in 60 (26%) of those randomized to maribavir, including 49 (48%) of 103 nonresponders and 25 (86%) of the 29 nonresponders where viral DNA initially cleared then rebounded while on maribavir. The most common maribavir resistance mutations were UL97 T409M (n = 34), H411Y (n = 26), and C480F (n = 21), first detected 26 to 130 (median 56) days after starting maribavir., Conclusions: Baseline maribavir resistance was rare. Drug resistance to standard cytomegalovirus antivirals did not preclude treatment response to maribavir. Rebound in plasma cytomegalovirus DNA while on maribavir strongly suggests emerging drug resistance., Clinical Trials Registration: NCT02931539., Competing Interests: Potential conflicts of interest . J. J. W., R. A. M., and M. F. are Takeda employees and stockholders. N. E. B. is a paid consultant for Takeda. S. A. reports research grants or contracts paid to institution from BioMérieux, Biotest, Elitech, Hologic, Merck, Merck Sharp & Dohme, and Takeda; honoraria for lectures paid to institution from Biotest, Merck Sharp & Dohme France, and Takeda; support for attending meetings from Biotest, Merck Sharp & Dohme France; advisory board paid to institution from Biotest, Merck Sharp & Dohme, and Takeda; and primary investigator for Solstice 303 study in France. C. C. reports consulting fees from Merck and Takeda; honoraria for lectures from Avir Pharma and Takeda; and advisory board membership for Takeda. R. F. C. reports consultancy fees from Merck/MSD, Oxford Immunotec, Takeda, and Viracor-Eurofins. C. N. K. reports paid consultant/clinical trial adjudication, honoraria for lectures, meeting support, and expert testimony for Takeda. J. L. reports research grants from the Danish Government, Danish National Research Foundation, and National Institutes of Allergy and Infectious Diseases. G. A. P. has received partial funding from P30 CA008748 Cancer Center Support Grant; and consulting fees from AlloVir, Cidara, Octapharma, Takeda, MSK, Symbio, and Vera Armatta; research funding paid to the institution from MSD and Takeda; and honoraria from MSD. M. R. P. reports consulting fees from Union Therapeutics; honoraria for presentations from Takeda; and advisory board membership for Takeda. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Published: 2024
Full Text: View/download PDF

24. Differences in toll-like receptor ligand-induced cytokine concentrations before and after solid organ transplantation: A prospective, observational cohort study in a clinical setting.

Author: Møller DL, Sørensen SS, Perch M, Gustafsson F, Hald A, Knudsen AD, Abdulovski R, Arentoft NS, Lundgren J, Rasmussen A, Ostrowski SR, and Nielsen SD
Subjects: Humans, Interleukin-10, Ligands, Lipopolysaccharides, Prospective Studies, Toll-Like Receptors, Methylprednisolone, Poly I, Cytokines, Organ Transplantation
Abstract: Reliable methods to assess immune function after solid organ transplantation (SOT) are needed to guide dosing of immunosuppression. We hypothesized that toll-like receptor ligand-induced cytokine concentrations would decrease post-transplantation due to the use of immunosuppressive medication. Furthermore, we hypothesized that induced cytokine concentrations pre-transplantation would be higher in recipients with episodes of acute rejection post-transplantation due to underlying immunological dispositions. We aimed to investigate toll-like receptor ligand-induced cytokine concentrations by TruCulture©, a standardized immunoassay, in SOT recipients before and 3 months after SOT and explored associations with methylprednisolone-treated acute rejections. We conducted a prospective, observational cohort study including 123 participants (67 liver, 32 kidney and 24 lung transplant recipients). Whole blood was stimulated for 22 h with: (A) Lipopolysaccharide (LPS), (B) Resiquimod, (C) Polyinosinic:polycytidylic acid (Poly I:C) and (D) a blank control. Cytokine concentrations (TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12p40, IL-17A, IFN-α and IFN-γ) were measured by Luminex. 30 participants developed methylprednisolone-treated acute rejection at a median of 9 days (IQR 5-17) post-SOT. We found that all induced cytokine concentrations decreased post-SOT except from LPS-induced and Poly I:C-induced IL-10. The induced cytokine concentration pre-transplantation did not differ in recipients with or without acute rejection. In conclusion, the induced cytokine concentrations decreased for all stimuli post-SOT, except the anti-inflammatory cytokine IL-10. Importantly, recipients developing early acute rejection did not differ in induced cytokine concentrations pre-SOT. Thus, the use of a standardized assay in SOT is feasible in a clinical setting and may provide important information on the immune function post-SOT., (© 2023 The Scandinavian Foundation for Immunology.)
Published: 2024
Full Text: View/download PDF

25. Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.

Author: Cozzi-Lepri A, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J, and Baxter JD
Subjects: Humans, Reverse Transcriptase Inhibitors therapeutic use, High-Throughput Nucleotide Sequencing, Viral Load, Drug Resistance, Viral genetics, HIV Infections epidemiology, HIV-1 genetics, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, HIV Seropositivity drug therapy
Abstract: Objectives: The main objective of this analysis was to evaluate the impact of pre-existing drug resistance by next-generation sequencing (NGS) on the risk of treatment failure (TF) of first-line regimens in participants enrolled in the START study., Methods: Stored plasma from participants with entry HIV RNA >1000 copies/mL were analysed using NGS (llumina MiSeq). Pre-existing drug resistance was defined using the mutations considered by the Stanford HIV Drug Resistance Database (HIVDB v8.6) to calculate the genotypic susceptibility score (GSS, estimating the number of active drugs) for the first-line regimen at the detection threshold windows of >20%, >5%, and >2% of the viral population. Survival analysis was conducted to evaluate the association between the GSS and risk of TF (viral load >200 copies/mL plus treatment change)., Results: Baseline NGS data were available for 1380 antiretroviral therapy (ART)-naïve participants enrolled over 2009-2013. First-line ART included a non-nucleoside reverse transcriptase inhibitor (NNRTI) in 976 (71%), a boosted protease inhibitor in 297 (22%), or an integrase strand transfer inhibitor in 107 (8%). The proportions of participants with GSS <3 were 7% for >20%, 10% for >5%, and 17% for the >2% thresholds, respectively. The adjusted hazard ratio of TF associated with a GSS of 0-2.75 versus 3 in the subset of participants with mutations detected at the >2% threshold was 1.66 (95% confidence interval 1.01-2.74; p = 0.05) and 2.32 (95% confidence interval 1.32-4.09; p = 0.003) after restricting the analysis to participants who started an NNRTI-based regimen., Conclusions: Up to 17% of participants initiated ART with a GSS <3 on the basis of NGS data. Minority variants were predictive of TF, especially for participants starting NNRTI-based regimens., (© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
Published: 2024
Full Text: View/download PDF

26. Neurocognitive development after pediatric brain tumor - a longitudinal, retrospective cohort study.

Author: Tonning Olsson I, Lundgren J, Hjorth L, Munck Af Rosenschöld P, Hammar Å, and Perrin S
Subjects: Child, Humans, Male, Retrospective Studies, Cranial Irradiation, Survivors, Brain Neoplasms psychology
Abstract: Survivors of Pediatric Brain Tumors (PBTs) treated with cranial radiation therapy (CRT) often experience a decline in neurocognitive test scores. Less is known about the neurocognitive development of non-irradiated survivors of PBTs. The aim of this study was to statistically model neurocognitive development after PBT in both irradiated and non-irradiated survivors and to find clinical variables associated with the rate of decline in neurocognitive scores. A total of 151 survivors were included in the study. Inclusion criteria: Diagnosis of PBT between 2001 and 2013 or earlier diagnosis of PBT and turning 18 years of age between 2006 and 2013. Exclusion criteria: Death within a year from diagnosis, neurocutaneous syndromes, severe intellectual disability. Clinical neurocognitive data were collected retrospectively from medical records. Multilevel linear modeling was used to evaluate the rate of decline in neurocognitive measures and factors associated with the same. A decline was found in most measures for both irradiated and non-irradiated survivors. Ventriculo-peritoneal (VP) shunting and treatment with whole-brain radiation therapy (WBRT) were associated with a faster decline in neurocognitive scores. Male sex and supratentorial lateral tumor were associated with lower scores. Verbal learning measures were either stable or improving. Survivors of PBTs show a pattern of decline in neurocognitive scores irrespective of treatment received, which suggests the need for routine screening for neurocognitive rehabilitation. However, survivors treated with WBRT and/or a VP shunt declined at a faster rate and appear to be at the highest risk of negative neurocognitive outcomes and to have the greatest need for neurocognitive rehabilitation.
Published: 2024
Full Text: View/download PDF

27. Adolescents' self-reported experiences following a person-centred, theory-based educational intervention versus conventional education for improved oral hygiene: Analysis of secondary outcomes of a randomized field study.

Author: Dimenäs SL, Andersson JS, Jönsson B, Lundgren J, Petzold M, Östberg AL, and Abrahamsson KH
Subjects: Adolescent, Humans, Prospective Studies, Self Report, Surveys and Questionnaires, Randomized Controlled Trials as Topic, Gingivitis, Oral Hygiene psychology
Abstract: Aim: To analyse adolescents' self-reported experiences and behavioural outcomes of a person-centred, theory-based intervention in comparison with conventional information/instruction for improved oral hygiene., Materials and Methods: Data were derived from a prospective, multi-centred, two-arm, quasi-randomized field study focusing on the effectiveness of educational interventions for improved oral hygiene. Dental hygienists working within the Public Dental Service, Västra Götaland, Sweden, provided treatments, and adolescents with poor oral hygiene conditions were eligible for participation. The person-centred test intervention was based on social cognitive constructs, and motivational interviewing was used as an approach in communication. The control intervention included conventional information/instructions. Clinical examinations were performed, and questionnaires were distributed at baseline and at 6 months. Three-hundred and twelve patients were enrolled, and data from 276 patients, following treatment per protocol, were analysed., Results: The test group was more satisfied with the education about gingivitis (very good: 61% vs. 37%) and communication during therapy (very good: 69% vs. 50%) and reported to a larger extent that they were much more careful regarding their oral hygiene after the treatment (30% vs. 15%) and had higher confidence about keeping up healthy gingival conditions, in comparison with the control group (all p < .01)., Conclusions: The person-centred, theory-based intervention was superior in terms of adolescents' experiences of education and communication during therapy and self-reported oral hygiene behavioural outcomes at 6 months, in comparison with conventional information/instruction., (© 2023 The Authors. Journal of Clinical Periodontology published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

27 results on '"Lundgren, J."'

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Longitudinal Importance of the Soluble Receptor for Advanced Glycation End-products in COVID-19 Pneumonia

3. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

4. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

5. Combination of CO2 electrochemical reduction and biomass gasification for producing methanol : A techno-economic assessment

6. (379) - Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

7. (379) - Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing.

8. Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.

9. Management of Post-transplant Infections in Collaborating Hospitals (MATCH) Programme: a prospective cohort of all transplant recipients at Copenhagen University Hospital-Rigshospitalet, Denmark.

10. Changing from disease-centred to person-centred - Swedish dental hygienists' views on a theory-based behavioural intervention for improved oral hygiene among adolescents.

11. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study.

12. Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.

13. Impact of baseline SARS-CoV-2 load in plasma and upper airways on the incidence of acute extrapulmonary complications of COVID-19: a multicentric, prospective, cohort study.

14. Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19.

15. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.

16. E-therapists' views on the acceptability and feasibility of an internet-administered, guided, low-intensity cognitive behavioural therapy intervention for parents of children treated for cancer: A qualitative study.

17. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.

18. The effects of internet-based cognitive behaviour therapy for depression in cardiovascular disease on symptoms of anxiety: a secondary analysis of a randomized trial.

19. Cervical Spondylosis Diagnosis Based on Convolutional Neural Network with X-ray Images.

20. The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants.

21. Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.

22. Correlation of mitochondrial respiration in platelets, peripheral blood mononuclear cells and muscle fibers.

23. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.

24. Differences in toll-like receptor ligand-induced cytokine concentrations before and after solid organ transplantation: A prospective, observational cohort study in a clinical setting.

25. Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.

26. Neurocognitive development after pediatric brain tumor - a longitudinal, retrospective cohort study.

27. Adolescents' self-reported experiences following a person-centred, theory-based educational intervention versus conventional education for improved oral hygiene: Analysis of secondary outcomes of a randomized field study.

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

27 results on '"Lundgren, J."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources